Quotient Clinical, the Translational Pharmaceutics® Company, has announced the initiation of a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate, a marketed drug prescribed in combination with prednisone to patients suffering from metastatic prostate cancer.
The program will assess new formulations using DRGT’s proprietary Super-API technology, and aims to reduce dose and address food effects associated with the drug.
Quotient’s RapidFACT service provides formulation development, real-time GMP manufacturing and clinical testing, all in one location, creating a streamlined approach to optimizing drug formulations for clinical development. It has been proven to accelerate program timelines by at least 50 % and delivers significant cost savings.
Mark Egerton, CEO of Quotient Clinical, said: “We are delighted that DRGT has selected RapidFACT to support its formulation development project, targeting an important drug in the fight against prostate cancer. This program of work is an excellent illustration of how we can work with our emerging biopharma customers to rapidly validate novel drug delivery technologies and new product concepts.”
Gabor Heltovics, CEO of Druggability technologies, added: “We are very pleased to be working with Quotient on this very important Super-API clinical development program that promises to achieve a major dose reduction, combined with a substantial reduction or elimination of the significant food effects of the marketed drug. The successful application of our Super-API technology to abiratone acetate is yet another important milestone in the development of our oncology drug product portfolio, with the potential to improve the quality of life of patients and help unlock the full potential of drugs that prolong and save lives.”